WELCOME TO VIRTUAL DISCOVERY
A Galaxy of Small Molecule Drugs Awaits
At Virtual Discovery, we have a vision of a world in which every disease can be cured.
Our mission is to help pharmaceutical companies discover new therapeutics using technologies that are dramatically faster and cheaper than traditional wet-lab methods
WHAT WE OFFER
We discover potent hit and lead compounds using ultra-large virtual screenings (on the order of billions of small molecules)
We optimize hit and lead compounds by screening hundreds of thousands of analogs against a particular target
WHY VIRTUAL DISCOVERY?
Since we can explore the chemical space far more thoroughly than traditional methods, our hits are usually better in terms of binding affinity and other ADMET related properties
We can screen billions of compounds in a matter of days.
Screening in silico is dramatically cheaper than traditional wet-lab-based methods like HTS
WHO WE ARE
DR. GERHARD WAGNER, FOUNDER
Dr. Gerhard Wagner, Elkan Blout Professor of Biological Chemistry and Molecular Pharmacology, Biological Chemistry and Molecular Pharmacology, Harvard Medical School, is an elected fellow of the American Association for the Advancement of Science, German National Academy, American Academy of Arts and Sciences, National Academy of Science, and International Society of Magnetic Resonance. Dr. Wagner is experienced in computational drug discovery, and he supervises the VirtualFlow project. His work includes identifying small-molecule inhibitors of protein-protein interaction and their potential uses as anti-cancer agents.